IPO Update | Deshi Biotech's Hong Kong IPO Prospectus Lapses

Stock News

Dec 29, 2025

Hangzhou Deshi Biotechnology Co., Ltd. (Deshi Biotech) saw its Hong Kong IPO prospectus, submitted on June 29, lapse on December 29 after the six-month validity period expired. Huatai International acted as the sole sponsor at the time of the application. According to the prospectus, which cited Frost & Sullivan data, Deshi Biotech's self-developed iMedImageTM is recognized as the world's largest general-purpose medical imaging foundation model by parameter scale. The model has been successfully commercialized and is acknowledged as the world's first commercially available cross-modal medical imaging foundation model.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1189267109"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1189267109\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1189267109?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-29 19:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189267109","market":"us","top_or_hot":-1,"title":"IPO Update | Deshi Biotech's Hong Kong IPO Prospectus Lapses","media":"Stock News","content":"<p>Hangzhou Deshi Biotechnology Co., Ltd. (Deshi Biotech) saw its Hong Kong IPO prospectus, submitted on June 29, lapse on December 29 after the six-month validity period expired. Huatai International acted as the sole sponsor at the time of the application.\nAccording to the prospectus, which cited Frost & Sullivan data, Deshi Biotech's self-developed iMedImageTM is recognized as the world's largest general-purpose medical imaging foundation model by parameter scale. The model has been successfully commercialized and is acknowledged as the world's first commercially available cross-modal medical imaging foundation model.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Update | Deshi Biotech's Hong Kong IPO Prospectus Lapses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Update | Deshi Biotech's Hong Kong IPO Prospectus Lapses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-29 19:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hangzhou Deshi Biotechnology Co., Ltd. (Deshi Biotech) saw its Hong Kong IPO prospectus, submitted on June 29, lapse on December 29 after the six-month validity period expired. Huatai International acted as the sole sponsor at the time of the application.\nAccording to the prospectus, which cited Frost & Sullivan data, Deshi Biotech's self-developed iMedImageTM is recognized as the world's largest general-purpose medical imaging foundation model by parameter scale. The model has been successfully commercialized and is acknowledged as the world's first commercially available cross-modal medical imaging foundation model.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"91016","symbol_name":"杭州德适生物科技股份有限公司（临时代码）","start_time":0,"source_url":"","article_id":"1189267109","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189267109","pubTimestamp":1767006865,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hangzhou Deshi Biotechnology Co., Ltd. (Deshi Biotech) saw its Hong Kong IPO prospectus, submitted on June 29, lapse on December 29 after the six-month validity period expired. Huatai International...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"91016":"杭州德适生物科技股份有限公司（临时代码）"},"translate_title":"IPO动态|德实生物港股IPO招股书失效","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91016":1},"content_text":"Hangzhou Deshi Biotechnology Co., Ltd. (Deshi Biotech) saw its Hong Kong IPO prospectus, submitted on June 29, lapse on December 29 after the six-month validity period expired. Huatai International acted as the sole sponsor at the time of the application.\nAccording to the prospectus, which cited Frost & Sullivan data, Deshi Biotech's self-developed iMedImageTM is recognized as the world's largest general-purpose medical imaging foundation model by parameter scale. The model has been successfully commercialized and is acknowledged as the world's first commercially available cross-modal medical imaging foundation model.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}